Company news
Addex Therapeutics Ltd (SIX:ADXN) news
Addex Therapeutics Ltd news releases on 6ix. Latest, Oct 2, 2026: Addex Therapeutics Announces Executive Management Changes
Press releases & updates
Addex Therapeutics Announces Executive Management Changes
October 2, 2026
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
September 28, 2026
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
September 25, 2026
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
September 24, 2026
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
August 26, 2026
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
July 8, 2026
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
June 25, 2026
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
June 22, 2026
Addex Therapeutics : Invitation ( 432)
June 5, 2026
Addex Convenes Annual General Meeting 2026
June 5, 2026
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
April 30, 2026
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
April 29, 2026
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
April 23, 2026
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
April 21, 2026
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
February 3, 2026
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
January 7, 2026
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
December 11, 2025
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
December 4, 2025
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
December 1, 2025
Addex Increases Issued Share Capital to Create Treasury Shares
October 29, 2025
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
September 30, 2025
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
September 26, 2025
Addex Appoints Bank of New York Mellon as Depositary Bank
September 23, 2025
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
June 30, 2025
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 25, 2025
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
June 19, 2025
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
June 18, 2025
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
June 6, 2025
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
June 5, 2025
Addex Convenes Annual General Meeting 2025
June 3, 2025
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
May 12, 2025
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
April 30, 2025
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
April 25, 2025
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
April 24, 2025
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
April 17, 2025